Medicamentsen-ligne vous propose les traitements dont vous avez besoin afin de prendre soin de votre santé sexuelle. Avec plus de 6 ans d'expérience et plus de 90.000 clients francophones, nous étions la première clinique fournissant du acheter kamagra original en France à vente en ligne et le premier vendeur en ligne de Kamagra dans le monde. Pourquoi prendre des risques si vous pouvez être sûr avec Medicamentsen-ligne - Le service auquel vous pouvez faire confiance.

Microsoft word - publikationsliste.doc

Neuhausen SL, Brummel S, Ding YC, Steele L, Nathanson KL, Domchek S,
Rebbeck TR, Singer CF, Pfeiler G, Lynch HT, Garber JE, Couch F, Weitzel JN,
Godwin A, Narod SA, Ganz PA, Daly MB, Isaacs C, Olopade OI, Tomlinson GE,
Rubinstein WS, Tung N, Blum JL, Gil en DL. Genetic Variation in IGF2 and
HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers.

Cancer Epidemiol Biomarkers Prev. 2011 Jul 26. Antoniou AC, Kartsonaki C, Sinilnikova OM,……….Pfeiler G, ………… Easton
DF, Chenevix-Trench G; on behalf of CIMBA. Common al eles at 6q25.1 and
1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation
carriers.

IF: 7.386
Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger
S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V,
Greil R, Marth C, Gnant M. Impact of Body Mass Index on the Efficacy of
Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis
of the Prospective ABCSG-12 Trial.

IF: 17.793
Königsberg R, Obermayr E, Bises G, Pfeiler G, Gneist M, Wrba F, De Santis M,
Zeil inger R, Hudec M, Dittrich C. Detection of EpCAM positive and negative
circulating tumor cel s in metastatic breast cancer patients.

IF: 2.265
Königsberg R*, Pfeiler G*, Kurzawa R, Hudec M, Zeil inger R, Dittrich C, Singer
C. Prognostic assessment and adjuvant treatment strategies within early-stage,
sporadic triple negative breast cancer patients.

IF: 2.105
Pfeiler G, Glatz C, Königsberg R, Geisendorfer T, Fink-Retter A, Kubista E,
Singer C, Seifert M Vaginal estriol to overcome side effects of aromatase
inhibitors in breast cancer patients

Climacteric 2011 Jan; 1: 1-6
IF: 2.568
Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-
Trench G, Spurdle AB, Beesley J, Chen X, Healey S; KConFab, Neuhausen SL,
Ding YC, Couch FJ, Wang X, Lindor N, Manoukian S, Barile M, Viel A, Tizzoni L,
Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai P, Rennert G,
Lejbkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H, Weerasooriya N; OCGN,
Gerdes AM, Thomassen M, Cruger DG, Caligo MA, Friedman E, Kaufman B,
Laitman Y, Cohen S, Kontorovich T, Gershoni-Baruch R, Dagan E, Jernström H,
Askmalm MS, Arver B, Malmer B; SWE-BRCA, Domchek SM, Nathanson KL,
Brunet J, Ramón Y Cajal T, Yannoukakos D, Hamann U; HEBON, Hogervorst FB,
Verhoef S, Gómez García EB, Wijnen JT, van den Ouweland A; EMBRACE,
Easton DF, Peock S, Cook M, Oliver CT, Frost D, Luccarini C, Evans DG, Lal oo
F, Eeles R, Pichert G, Cook J, Hodgson S, Morrison PJ, Douglas F, Godwin AK;
GEMO, Sinilnikova OM, Barjhoux L, Stoppa-Lyonnet D, Moncoutier V, Giraud S,
Cassini C, Olivier-Faivre L, Révil ion F, Peyrat JP, Mul er D, Fricker JP, Lynch HT,
John EM, Buys S, Daly M, Hopper JL, Terry MB, Miron A, Yassin Y, Goldgar D;
Breast Cancer Family Registry, Singer CF, Gschwantler-Kaulich D, Pfeiler G,
Spiess AC, Hansen TV, Johannsson OT, Kirchhoff T, Offit K, Kosarin K, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casel a C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Deissler H, Fiebig B, Varon-Mateeva R, Schaefer D, Froster UG, Caldes T, de la Hoya M, McGuffog L, Antoniou AC, Nevanlinna H, Radice P, Benítez J; CMBA. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). Br J Cancer. 2009 Dec 15;101(12):2048-54. IF: 4.346
Walker LC, Fredericksen ZS, Wang X, Tarrel R, Pankratz VS, Lindor NM,
Beesley J, Healey S, Chen X; kConFab, Stoppa-Lyonnet D, Tirapo C, Giraud S,
Mazoyer S, Mul er D, Fricker JP, Delnatte C; GEMO Study Col aborators,
Schmutzler RK, Wappenschmidt B, Engel C, Schönbuchner I, Deissler H, Meindl
A, Hogervorst FB, Verheus M, Hooning MJ, van den Ouweland AM, Nelen MR,
Ausems MG, Aalfs CM, van Asperen CJ, Devilee P, Gerrits MM, Waisfisz Q;
HEBON, Szabo CI; ModSQuaD, Easton DF, Peock S, Cook M, Oliver CT, Frost
D, Harrington P, Evans DG, Lal oo F, Eeles R, Izatt L, Chu C, Davidson R, Eccles
D, Ong KR, Cook J; EMBRACE, Rebbeck T, Nathanson KL, Domchek SM, Singer
CF, Gschwantler-Kaulich D, Dressler AC, Pfeiler G, Godwin AK, Heikkinen T,
Nevanlinna H, Agnarsson BA, Caligo MA, Olsson H, Kristoffersson U, Liljegren A,
Arver B, Karlsson P, Melin B; SWE-BRCA, Sinilnikova OM, McGuffog L, Antoniou
AC, Chenevix-Trench G, Spurdle AB, Couch FJ. Evidence for SMAD3 as a
modifier of breast cancer risk in BRCA2 mutation carriers.

Breast Cancer Res. 2010 Nov 29;12(6):R102. IF: 5.326
Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL,
Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G,
Olopade OI, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian
S, Peissel B, Zaffaroni D, Barile M, Viel A, Allavena A, Dal 'Olio V, Peterlongo P,
Szabo CI, Zikan M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert
G, Lejbkowicz F, Glendon G, Ozcelik H, Andrulis IL; Ontario Cancer Genetics
Network, Thomassen M, Gerdes AM, Sunde L, Cruger D, Birk Jensen U, Caligo
M, Friedman E, Kaufman B, Laitman Y, Milgrom R, Dubrovsky M, Cohen S, Borg
A, Jernström H, Lindblom A, Rantala J, Stenmark-Askmalm M, Melin B; SWE-
BRCA, Nathanson K, Domchek S, Jakubowska A, Lubinski J, Huzarski T, Osorio
A, Lasa A, Durán M, Tejada MI, Godino J, Benitez J, Hamann U, Kriege M,
Hoogerbrugge N, van der Luijt RB, van Asperen CJ, Devilee P, Meijers-Heijboer
EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M; HEBON, Cook M, Oliver C,
Frost D, Conroy D, Evans DG, Lal oo F, Pichert G, Davidson R, Cole T, Cook J,
Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ,
Dorkins H, Peock S; EMBRACE, Godwin AK, Stoppa-Lyonnet D, de Pauw A,
Mazoyer S, Bonadona V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P,
Faivre L; GEMO, Loustalot C, Noguchi T, Sobol H, Rouleau E, Nogues C, Frénay
M, Vénat-Bouvet L; GEMO, Hopper JL, Daly MB, Terry MB, John EM, Buys SS,
Yassin Y, Miron A, Goldgar D; Breast Cancer Family Registry, Singer CF,
Dressler AC, Gschwantler-Kaulich D, Pfeiler G, Hansen TV, Jønson L,
Agnarsson BA, Kirchhoff T, Offit K, Devlin V, Dutra-Clarke A, Piedmonte M,
Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland
AE, Montagna M, Casel a C, Imyanitov E, Tihomirova L, Blanco I, Lazaro C,
Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, Engel C, Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Kast K, Schönbuchner I, Caldes T, de la Hoya M, Aittomäki K, Nevanlinna H, Simard J, Spurdle AB, Hol and H, Chen X; kConFab, Platte R, Chenevix-Trench G, Easton DF; CIMBA. Common breast cancer susceptibility al eles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. IF: 7.543
Königsberg R, Gneist M, Jahn-Kuch D, Pfeiler G, Hager G, Hudec M, Dittrich C,
Zeil inger
Circulating tumor cel s in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods. IF: 3.741
Pfeiler G, Hudelist G, Wülfing P, Mattsson B, Königsberg R, Kubista E, Singer
CF. Impact of AdipoR1 expression on breast cancer development.
Gynecol Oncol. 2010 Apr;117(1):134-8.
IF: 3.733
Neuhausen SL, Brummel S, Ding YC, Singer CF, Pfeiler G, Lynch HT,
Nathanson KL, Rebbeck TR, Garber JE, Couch F, Weitzel J, Narod SA, Ganz PA,
Daly MB, Godwin AK, Isaacs C, Olopade OI, Tomlinson G, Rubinstein WS, Tung
N, Blum JL, Gil en DL.
Genetic variation in insulin-like growth factor signaling genes and breast cancer
risk among BRCA1 and BRCA2 carriers.

Breast Cancer Res. 2009;11(5):R76.
IF: 5.326
Rebbeck TR, Mitra N, Domchek SM, Wan F, Chuai S, Friebel TM, Panossian S,
Spurdle A, Chenevix-Trench G; kConFab, Singer CF, Pfeiler G, Neuhausen SL,
Lynch HT, Garber JE, Weitzel JN, Isaacs C, Couch F, Narod SA, Rubinstein WS,
Tomlinson GE, Ganz PA, Olopade OI, Tung N, Blum JL, Greenberg R, Nathanson
KL, Daly MB.
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. IF: 7.543
Pfeiler G, Treeck O, Wenzel G, Goerse R, Hartmann A, Schmitz G, Ortmann O.
Influence of insulin resistance on adiponectin receptor expression in breast
cancer.

IF: 2.093
Pfeiler G, Wenzl G, Schmitz G, Hartmann A, Treeck O, Ortmann O.
Correlation of body mass index and menopausal status with the intratumoral
estrogen system in invasive breast cancer

Gynecol Endocrinol. 2009 Mar;25(3):183-7.
IF: 1.360
Szendroedi J, Anderwald C, Krssak M, Bayerle-Eder M, Esterbauer H, Pfeiler G,
Brehm
Effects of high dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in non-obese type 2 diabetic patients. IF: 6.718
Singer CF, Gschwantler-Kaulich D, Fink-Retter A, Pfeiler G, Walter I, Hudelist G,
Helmy S, Spiess AC, Lamm W, Kubista E.
HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive
early breast cancer.
J Cancer Res Clin Oncol. 2008 Nov 26.
IF: 2.261

Treeck O, Lattrich C, Juhasz-Boess I, Buchholz S, Pfeiler G, Ortmann O.
Adiponectin differential y affects gene expression in human mammary epithelial
and breast cancer cel s.
Br J Cancer. 2008 Oct 21;99(8):1246-50
IF: 4.346

Hudelist G, Wuelfing P, Czerwenka K, Knöfler M, Haider S, Fink-Retter A,
Gschwantler-Kaulich D, Pfeiler G, Kubista E, Singer CF.
Beta-hCG/LH receptor (b-HCG/LH-R) expression is increased in invasive versus
preinvasive breast cancer: implications for breast carcinogenesis?
J Cancer Res Clin Oncol. 2008 Aug 29.
IF: 2.261

Anderwald C, Pfeiler G, Nowotny P, Anderwald-Stadler M, Krebs M, Bischof MG,
Kozakova M, Luger A, Pacini G, Roden M, Waldhäusl W.
Glucose turnover and intima media thickness of internal carotid artery in type 2

Eur J Clin Invest. 2008 Apr;38(4):227-37 IF : 2.643
Pfeiler G, Buechler C, Neumeier M, Schäffler A, Schmitz G, Ortmann O, Treeck O. Adiponectin effects on human breast cancer cel s are dependent on 17-β estradiol IF: 1.588

Pfeiler G, Horn F, Lattrich C, Klappenberger S, Ortmann O, Treeck O.
Apoptotic effects of signal transduction inhibitors on human tumor cel s with
different PTEN expression.

Oncol Rep. 2007 Nov;18(5):1305-9.
IF: 1.588

Pfeiler G*
, Treeck O*, Mitter D, Lattrich C, Piendl G, Ortmann O.
Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer
cel s.
J Endocrinol. 2007 Jun;193(3):421-33.
IF: 3.045

Weiss JM, Hul er H, Polack S, Friedrich M, Diedrich K, Treeck O, Pfeiler G,
Ortmann O.
Estradiol differential y modulates the exocytotic proteins SNAP-25 and munc-18 in
pituitary
gonadotrophs.
J Mol Endocrinol. 2007 Feb;38(1-2):305-14.
IF: 3.221

Treeck O, Pfeiler G, Horn F, Federhofer B, Houlihan H, Vol mer A, Ortmann O.
Novel estrogen receptor beta transcript variants identified in human breast cancer
cel s affect cel growth and apoptosis of COS-1 cel s.

Mol Cel Endocrinol. 2007 Jan 29;264(1-2):50-60. IF: 3.503
Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M.
Relationship between serum lipoprotein ratios and insulin resistance in obesity.
Clin Chem. 2004 Dec;50(12):2316-22.
IF: 2.066

Source: http://www.womenshealth.at/wp-content/uploads/2010/12/PublikationslisteI.pdf

traveldoctor.com.au

Malarone® Tablets (250/100) Junior Tablets (62.5/25) (Atovaquone and Proguanil Hydrochloride) Consumer Medicine Information you are taking any medicines containing Do not stop taking Malarone, or change the warfarin, rifampicin, rifabutin, dose without first checking with your doctor. Unless explained differently, the information for tetracycline, metoclopramide or indinavir.

Microsoft word - 2011 ku broschuere artikel 01-2004 bis 06-2011.doc

Sicherheit geht vor Schutz vor gefälschten Arzneimitteln durch neue EU-Richtlinie Mit einer neuen EU-Richtlinie werden harmonisierte, gesamteuropäische Sicherheitsmaßnahmen sowie Maßnahmen gegen den Verkauf gefälschter Arzneimittel über das Internet eingeführt. Diese Maßnah-men sollen es erleichtern, gefälschte Arzneimittel zu erkennen, und Kontrollen sowie Überprüfungen an den

Copyright © 2010-2014 Pharmacy Pills Pdf